Neuro

Easy Way to Live Introduces the Neuro Transformative Pathway (NTP) Hypnosis Program

Retrieved on: 
onsdag, maj 29, 2024
Well, Online, NTP, Neuroscience, Hypnosis, Growth, Neuro, Brain, Suggestion, Habit

Easy Way to Live Well launches NTP Hypnosis Program with Leticia Oliveira, offering personalized, rapid transformation for global clients.

Key Points: 
  • La Jolla, California--(Newsfile Corp. - May 29, 2024) - Easy Way to Live Well announces the launch of their groundbreaking Neuro Transformative Pathway (NTP) Hypnosis Program, designed to revolutionize the way individuals harness the power of their minds for personal transformation and growth.
  • Unlocking the Power of the Mind: Easy Way to Live Introduces the Neuro Transformative Pathway (NTP) Hypnosis Program
    To view an enhanced version of this graphic, please visit:
    The Neuro Transformative Pathway (NTP) Hypnosis Program, developed by a team of leading experts in hypnotherapy and neuroscience, combines the latest advancements in hypnotic techniques with principles of neuroplasticity to create lasting and profound change.
  • "We are thrilled to introduce the Neuro Transformative Pathway (NTP) Hypnosis Program to the world," said Leticia Oliveira, Founder and CEO of Easy Way to Live Well.
  • To learn more about the Neuro Transformative Pathway (NTP) Hypnosis Program and to sign up for the next cohort, visit https://easywaytolivewell.com/neuro .

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
onsdag, maj 15, 2024
Cancer, Neuro, Molecular imaging, Feasibility, Patient, Ependymoma, Plus Therapeutics, Treatment, SNMMI, FDA, IND, CED, Anticipation, Therapy, Trial of the century, Conference, Breast cancer, Society, Nuclear medicine, Acquisition, PSTV, Spinal cord, LM, Completeness, Safety, Meninges, Webcast, Biomarker, Annual general meeting, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.
  • Additional detail on the acquisition can be found here
    Strengthened management team with appointments of neuro-oncologist Andrew Brenner, M.D.
  • Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
  • The webcast will be available on the Company’s website for 90 days following the live call.

Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

Retrieved on: 
onsdag, maj 22, 2024
Technology, Medical Devices, Diabetes, Cardiology, Software, Other Health, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Blood pressure, Neuro, LDL, Patient, MASH, Hyperlipidemia, Obesity, FDA, Therapy, Digital, Disease, Migraine, Opioid use disorder, Boehringer Ingelheim, Hypertension, Psychiatry, Research, CNS, Acquisition, DSM-IV codes, Environment, Schizophrenia, Psychology, Pharmaceutical industry

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.

Key Points: 
  • Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
  • This acquisition strengthens Click’s portfolio of innovative digital treatments for patients by immediately advancing its pipeline in obesity, diabetes and cardiometabolic diseases, complementing existing assets in psychiatry, CNS and pain disorders.
  • Click’s advancement into obesity and cardiometabolic disease is a culmination of progress over the past few years including the initiation of CT-181, a prescription digital therapeutic candidate for obesity.
  • “There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, Chief Commercial Officer of Click Therapeutics.

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Retrieved on: 
torsdag, maj 9, 2024
Plus Therapeutics, Northwestern University, LM, PSTV, Hematology, Breast, Lung cancer, CNS, Incidence, Patient, Acquisition, MRI, Neuro, Central nervous system, Clinical trial, Plus, Associate, Therapy, Cancer, Medical imaging

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

Key Points: 
  • Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™” and discussed potential partnering opportunities
    AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.
  • “Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern University & The Feinberg School of Medicine.
  • Plus discussed its plan to develop the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate rhenium (Re186) obisbemeda, and to seek partnering opportunities for CNSide.
  • Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO.
    “Better diagnostics for leptomeningeal metastases are a clinical imperative for these patients and will help increase the market for our lead radiotherapeutic candidate rhenium (Re186) obisbemeda,” said Dr. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.

Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation

Retrieved on: 
onsdag, maj 8, 2024
Family, Research, SAC, Glioblastoma, Patient safety, Brain, Patient, Metastasis, Anesthetic, LHSC, Lawson Health Research Institute, London Health Sciences Centre, Neuro, Medical imaging

The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.

Key Points: 
  • The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.
  • The work aims to assess whether anesthetics used during glioblastoma brain tumour surgery can impact tumour growth, invasion, and metastasis.
  • This grant reflects our commitment to supporting innovative research that can lead to better outcomes for brain cancer patients," she said.
  • Our team thanks Brain Cancer Canada, the Andrews Family and Auto|One Group for helping us kickstart our work through the Dwayne Andrews GBM Research Grant.”
    The grant is the first in a series of four to be issued by Brain Cancer Canada during May, Brain Cancer Awareness Month.

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Retrieved on: 
onsdag, maj 8, 2024
Neuroprotection, Inflammation, Hospital, Safety, OCS, Diabetic retinopathy, Apoptosis, Optic neuritis, AON, IND, Disease, Patient, Paratriathlon, Geographic atrophy, Optic nerve, Neuron, Glaucoma, Ophthalmology, Neuro, Pharmaceutical industry

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.

Key Points: 
  • The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.
  • OCS-05 has been granted orphan drug designation in both the United States and Europe, highlighting the importance of this unmet medical need.
  • In the meantime, we keep on working towards an IND submission for OCS-05 in the U.S. in 2024.
  • While corticosteroids are used to shorten the attack, there is no approved therapy for AON and unmet needs remain for therapies that can prevent vision loss after an acute episode of optic neuritis.

ClearPoint Neuro Reports First Quarter 2024 Results

Retrieved on: 
tisdag, maj 7, 2024
FDA, Brain, IDE, Software, Workflow, Prism, Interface (computing), Spine, Record, Paper, MRI, BLA, Marketing, Therapy, Telephone, SmartFrame, Growth, Neuro, Cryptocurrency

SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.
  • “Our ClearPoint Neuro team enjoyed the best operating performance in our Company’s history, with contributions coming from all four of our growth pillars,” commented Joe Burnett, President and CEO at ClearPoint Neuro.
  • Financial Results – Quarter Ended March 31, 2024
    Total revenue was $7.6 million for the three months ended March 31, 2024, and $5.4 million for the three months ended March 31, 2023, which represents an increase of $2.2 million, or 41%.
  • Operating expenses for the first quarter of 2024 were $8.8 million, compared to $8.9 million for the first quarter of 2023.

Verasonics Announces New OEM Supply Model to Enhance Suite of Offerings Available to Commercial Customers

Retrieved on: 
onsdag, maj 8, 2024
Medical Devices, Health, Health Technology, Other Science, Research, Science, Neuro, Breast imaging, High-intensity focused ultrasound, 3D printing

Verasonics, Inc., the leader in research ultrasound, announces a new OEM Supply Model to enhance corporate commercialization efforts for customers bringing ultrasound-based solutions to market.

Key Points: 
  • Verasonics, Inc., the leader in research ultrasound, announces a new OEM Supply Model to enhance corporate commercialization efforts for customers bringing ultrasound-based solutions to market.
  • Verasonics’ commercial suite of solutions now offers the Commercial Technology Licensing Model and the OEM Supply Model.
  • “By working with Verasonics and utilizing our innovative development platform, commercial licensees achieve substantial savings in development costs, and improved time to market.”
    Mr. Daigle added, “We are excited to add the OEM Supply Model to our suite of offerings available to commercial customers.
  • This program offers our customers additional flexibility and an alternate path for commercial supply.”
    For more information on Verasonics’ commercial suite of solutions, please contact [email protected] .

Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products

Retrieved on: 
onsdag, maj 8, 2024
Medical Devices, Surgery, Medical Supplies, FDA, Biometrics, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Collagen, News, Food, HCA, Surgeon, Spine, Porosity, Chemistry, Food and Drug Administration, Architecture, Neuro

Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.

Key Points: 
  • Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.
  • Agilon Moldable is unique among moldable synthetic bone grafts, as it contains both collagen with an organic polymer carrier and Biogennix’s proprietary TrelCor granules.
  • "Receiving expanded indications for our flagship Agilon Moldable and Morpheus products is exciting news," said Chris MacDuff, Biogennix’s CEO.
  • Based on enthusiastic feedback from over 75,000 successful cases to date, we anticipate increased market adoption this year for both Agilon and Morpheus moldable products."

From Pioneers to Leaders: Thought Technology Ltd Celebrates its 50th Anniversary at AAPB Conference

Retrieved on: 
onsdag, maj 8, 2024
Education, Tech, Hospital, Certification, Health, Research, ISO, Mental health, Neuro, GSR, Multimedia, CE, Nursing

MONTREAL, May 8, 2024 /PRNewswire-PRWeb/ -- Thought Technology Ltd., a well-established name in the biofeedback equipment sector, is delighted to announce its 50th anniversary. Since its inception, the company has been at the forefront of innovation, providing cutting-edge solutions for biofeedback practitioners worldwide.

Key Points: 
  • The device helps people achieve self-regulation, as a means of keeping stress levels under control.
  • There are more than 450,000 units used worldwide, in thousands of hospitals for numerous health and stress management programs.
  • Asked about reaching this milestone, Thought Technology founder Dr. Hal Myers commented, "It's hard to believe we've been at this for five decades.
  • Thought Technology sponsors a number of workshops, taught by world authorities in their fields, to teach clinical skills and the effective use of biofeedback instrumentation.